Orally Active Peptidic Bradykinin B1 Receptor Antagonists Engineered from a Cyclotide Scaffold for Inflammatory Pain Treatment

Authors

  • Clarence T. T. Wong,

    1. School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551 (Singapore)
    Search for more papers by this author
  • Dr. Dewi K. Rowlands,

    1. Laboratory Animal Service Centre, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong (China)
    Search for more papers by this author
  • Dr. Chi-Hang Wong,

    1. School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551 (Singapore)
    2. Current address: State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong (China)
    Search for more papers by this author
  • Dr. Theodore W. C. Lo,

    1. Laboratory Animal Service Centre, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong (China)
    Search for more papers by this author
  • Giang K. T. Nguyen,

    1. School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551 (Singapore)
    Search for more papers by this author
  • Prof. Hoi-Yeung Li,

    1. School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551 (Singapore)
    Search for more papers by this author
  • Prof. James P. Tam

    Corresponding author
    1. School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551 (Singapore)
    • School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551 (Singapore)
    Search for more papers by this author

  • This research was supported by Biomedical Research Council (BMRC 09/1/22/19/612) of A*STAR and Academic Research Fund (ARC21/08) of Ministry of Education in Singapore.

Abstract

original image

Essbar: Durch Aufpropfen von natürlichen Peptid-Antagonisten auf das Cyclotid Kalata B1 wurden Peptide hergestellt, die nützliche oral verabreichbare Schmerzmittel sein könnten. Zum Beispiel wurde die gesamte Schleife 6 von Kalata B1 durch den peptidischen Bradykinin-B1-Rezeptor-Antagonisten DALK (rot im Schema) ersetzt, um den cyclischen Bradykinin-Antagonisten ckb-kal zu erhalten.

Ancillary